These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6153126)

  • 21. Evaluation of MENT on primary cell cultures from benign prostatic hyperplasia and prostate carcinoma.
    Mendoza P; Sánchez C; Contreras HR; Vergara J; Acevedo C; Cabezas J; Huidobro C; Noé G; Castellón EA
    Int J Androl; 2009 Dec; 32(6):607-15. PubMed ID: 18637152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer.
    Heracek J; Hampl R; Hill M; Starka L; Sachova J; Kuncova J; Eis V; Urban M; Mandys V
    Steroids; 2007 Apr; 72(4):375-80. PubMed ID: 17368496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum prolactin and tumors of the prostate: unchanged basal levels and lack of correlation to serum testosterone.
    Jacobi GH; Rathgen GH; Altwein JE
    J Endocrinol Invest; 1980; 3(1):15-8. PubMed ID: 6154729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hormonal status in prostatic disease.
    Frick J; Bartsch G
    Prog Clin Biol Res; 1976; 6():143-58. PubMed ID: 66687
    [No Abstract]   [Full Text] [Related]  

  • 25. Influence of radical prostatectomy on serum hormone levels.
    Miller LR; Partin AW; Chan DW; Bruzek DJ; Dobs AS; Epstein JI; Walsh PC
    J Urol; 1998 Aug; 160(2):449-53. PubMed ID: 9679896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer.
    van der Sluis TM; Vis AN; van Moorselaar RJ; Bui HN; Blankenstein MA; Meuleman EJ; Heijboer AC
    BJU Int; 2012 Jan; 109(2):176-82. PubMed ID: 21992222
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Value of testosterone, FSH and LH on plasma in patients with prostatic adenoma and carcinoma before and after different hormonal treatments].
    Garcia de la Peña E; Ramos F; Horcajada C; Cifuentes Delatte L; Vivanco F
    Rev Clin Esp; 1978 Jan; 148(1):19-23. PubMed ID: 76325
    [No Abstract]   [Full Text] [Related]  

  • 28. Total and SHBG-bound testosterone and 5 alpha-dihydrotestosterone serum concentrations in normal elderly men and patients with benign prostatic hypertrophy before and after removal of the adenoma.
    Lukkarinen O
    Br J Urol; 1980 Oct; 52(5):377-80. PubMed ID: 6159037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Testosterone levels in benign prostatic hypertrophy and prostate cancer.
    Mearini L; Costantini E; Zucchi A; Mearini E; Bini V; Cottini E; Porena M
    Urol Int; 2008; 80(2):134-40. PubMed ID: 18362481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia.
    Gann PH; Hennekens CH; Longcope C; Verhoek-Oftedahl W; Grodstein F; Stampfer MJ
    Prostate; 1995 Jan; 26(1):40-9. PubMed ID: 7531326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content.
    Forti G; Salerno R; Moneti G; Zoppi S; Fiorelli G; Marinoni T; Natali A; Costantini A; Serio M; Martini L
    J Clin Endocrinol Metab; 1989 Feb; 68(2):461-8. PubMed ID: 2465302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influences of dihydrotestosterone, testosterone, estradiol, progesterone, or prolactin on the cell kinetics of human hyperplastic prostatic tissue in organ culture.
    de Launoit Y; Kiss R; Jossa V; Coibion M; Paridaens RJ; De Backer E; Danguy AJ; Pasteels JL
    Prostate; 1988; 13(2):143-53. PubMed ID: 2459683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Some effects of orchiectomy, oestrogen treatment and radiation therapy in patients with prostatic carcinoma.
    Tomić R
    Scand J Urol Nephrol Suppl; 1983; 77():1-37. PubMed ID: 6426040
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of sex steroid hormones in benign prostatic hyperplasia.
    Asiedu B; Anang Y; Nyarko A; Doku DA; Amoah BY; Santa S; Ngala RA; Asare GA
    Aging Male; 2017 Mar; 20(1):17-22. PubMed ID: 28084142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of diethylstilbestrol and medroxyprogesterone acetate on kinetics and production of testosterone and dihydrotestosterone in patients with prostatic carcinoma.
    Nolten WE; Sholiton LJ; Srivastava LS; Knowles HC; Werk EE
    J Clin Endocrinol Metab; 1976 Dec; 43(6):1226-33. PubMed ID: 1002814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased urinary 5 alpha-androstane-3 alpha,17 beta-diol glucuronide excretion in patients with benign prostatic hyperplasia.
    Wright F; Poizat R; Bongini M; Bozzolan F; Doukani A; Mauvais-Jarvis P
    J Clin Endocrinol Metab; 1985 Feb; 60(2):294-8. PubMed ID: 2578133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of megestrol acetate (Megace) on steroid metabolism and steroid-protein binding in the human prostate.
    Geller J; Albert J; Geller S; Lopez D; Cantor T; Yen S
    J Clin Endocrinol Metab; 1976 Nov; 43(5):1000-8. PubMed ID: 62759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reduced circulating androgen bioactivity in patients with prostate cancer.
    Raivio T; Santti H; Schatzl G; Gsur A; Haidinger G; Palvimo JJ; Jänne OA; Madersbacher S
    Prostate; 2003 May; 55(3):194-8. PubMed ID: 12692785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of aging on endogenous level of 5 alpha-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate.
    Krieg M; Nass R; Tunn S
    J Clin Endocrinol Metab; 1993 Aug; 77(2):375-81. PubMed ID: 7688377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
    Clark RV; Hermann DJ; Cunningham GR; Wilson TH; Morrill BB; Hobbs S
    J Clin Endocrinol Metab; 2004 May; 89(5):2179-84. PubMed ID: 15126539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.